| Date | Title | Description |
| 02.09.2026 | FluoSphera powers ahead with Debiopharm and Leica Microsystems |
The new offering is designed to support the characterization of antibody-drug conjugates (ADCs), bispecific antibodies, therapeutic antibodies and other antibody-based modalities. Antibody candidates can be labeled using AbYlink™ and subse... |
| 14.07.2026 | Converging at BIO, ACROBiosystems Connects Emerging Innovation Assets with Global Strategic Opportunities | SAN DIEGO, July 14, 2026 /PRNewswire/ -- Ahead of the BIO International Convention, BIOSeedin Summer Innovation Partnering Summit was successfully held at Wyndham San Diego Bayside, California. Hosted by bioSeedin, the summit's discussion t... |
| 13.07.2026 | Octozi Secures $3M to Revolutionize Clinical Trial Data with Agentic AI | Octozi, a New York-based artificial intelligence company, recently secured $3 million in seed funding. This investment propels its agentic AI platform. The technology revolutionizes clinical trial data management. It automates crucial steps... |
| 11.07.2026 | Octozi Raises $3 Million Seed To Bring Agentic AI Into Clinical Trial Data Operations | Octozi, a New York City-based artificial intelligence company that automates clinical development workflows for pharmaceutical sponsors, has raised 3 million dollars in seed funding. Surface Ventures led the round, with participation from R... |
| 07.07.2026 | Octozi Raises $3M in Seed Funding to bring Agentic AI to Clinical Development | New York City, United States, July 7th, 2026, FinanceWire
Octozi, an artificial intelligence company that automates clinical development workflows for pharmaceutical sponsors, has raised $3 million in seed funding.
The round was led by Surf... |
| 23.04.2026 | ViewsML: $4.9 Million Seed Funding Raised To Commercialize AI-Powered Virtual Biomarker Staining Platform | ViewsML announced it has raised $4.9 million in an oversubscribed seed funding round to accelerate commercialization of its virtual biomarker staining platform. The round was led by Wittington Ventures, with participation from Continuum Hea... |
| 21.04.2026 | ViewsML Secures $4.9M for AI Biomarker Revolution | ViewsML secured $4.9M in seed funding. This fuels its AI-driven virtual biomarker platform. The technology extracts critical per-cell insights directly from standard H&E pathology images. It eliminates traditional immunohistochemistry. ... |
| 21.04.2026 | ViewsML Raises $4.9M for AI-Driven Virtual Biomarker Staining Platform | What You Should Know
The Funding: ViewsML, a company building the computational layer for biomarker discovery, has closed an oversubscribed $4.9M seed round led by Wittington Ventures, with significant strategic participation from Mayo Clin... |
| 20.04.2026 | ViewsML Raises $4.9M in Seed Funding | ViewsML, a Vancouver, BC, Canada-based biomarker discovery company, raised $4.9M in seed funding.
The round was led by Wittington Ventures with participation from Continuum Health Ventures, Mayo Clinic, RiSC Capital, Debiopharm, WUTIF, Defi... |
| 09.01.2026 | Pierre Fabre Laboratories and Iktos Announce an Integrated AI-Driven Drug Discovery Collaboration in Oncology | CASTRES, France and PARIS, Jan. 9, 2026 /PRNewswire/ -- Pierre Fabre Laboratories and Iktos, a global leader in Artificial Intelligence (AI) and Robotics on drug discovery, today announced an integrated drug discovery collaboration to ident... |
| 30.09.2025 | StratifAI erhält 12,5 Millionen – clockin bekommt 10 Millionen | Im #DealMonitor für den 30. September werfen wir einen Blick auf die wichtigsten, spannendsten und interessantesten Investments und Exits des Tages in der DACH-Region. Alle Deals der Vortage gibt es im großen und übersichtlichen #DealMonito... |
| 17.06.2025 | ViewsML and Debiopharm Collaborate to Advance Virtual Biomarker Technology in Drug Research | ViewsML Technologies
Debiopharm
Debiopharm taps ViewsML’s AI-driven platform to streamline biomarker detection in oncology research.
Working with ViewsML allows us to integrate advanced AI solutions into our biomarker research, optimizing o... |
| 12.09.2024 | ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors | ITM gains exclusive global development and commercialization rights to Debiopharm’s first-in-class, peptide-based theranostic pair which combines therapeutic compound, Debio 0228 ([177Lu]Lu-DPI-4452) and diagnostic imaging agent, Debio 0328... |
| 24.04.2024 | Risklick launches flagship product following an investment by Debiopharm |
Developing new therapies typically requires an average of ten years and costs up to two billion dollars for companies. The most time-consuming and costly aspect of this process is the clinical trials, which are mandatory for validating new... |
| 09.01.2024 | MedaSystems Secures Additional Funding from Debiopharm Innovation Fund to Accelerate Global Access to Pre-approval Treatment | MENLO PARK, Calif. & LAUSANNE, Switzerland–(BUSINESS WIRE)–January 9, 2024–
MedaSystems, a pioneer in software to provide access to pre-approval medicine, is pleased to announce additional funding from Debiopharm Innovation Fund, the st... |
| 29.09.2023 | Debiopharm launches new seed fund for cancer care & pharma R&D transformation | Read this article in:
Lausanne, Switzerland-based Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, has announced the launch of a new seed funding.
The fund plans to invest in up to 15 s... |
| 28.09.2023 | USD 3.4M to foster Tune Insight vision | |
| 28.09.2023 | Debiopharm Innovation Fund Launches Seed Funding Activity | Debiopharm Innovation Fund, the Lausanne, Switzerland-based strategic investment arm of Swiss biopharmaceutical company Debiopharm, with $150m under management, announced the launch of its new seed funding initiative.
It plans to deploy add... |
| 28.09.2023 | Debiopharm to invest in seed stage companies | |
| 25.05.2023 | Debiopharm Partners with Genedata to Digitalize Translational Research | By consolidating large amounts of diverse, multi-source data & making it easy for our teams to use, Genedata Profiler strengthens our innovative potential to ultimately allow us to bridge the gap between research & real-world applic... |
| 17.05.2023 | DEBIOPHARM LAUNCHES PHASE 1/2 COMBINATION TRIAL INVESTIGATING BRAIN-PENETRANT SELECTIVE WEE1 INHIBITOR FOR BRAIN CANCER PATIENTS | Glioblastomas (GBM) are among the most aggressive and lethal tumors of the central nervous system with a 5-year survival rate of only 6.8%.
Debiopharm is combining its potent, brain penetrant WEE1 inhibitor Debio 0123 with standard of care ... |
| 30.03.2023 | Slovenian Genialis raises ＄13M to improve diseases treatment with AI and ML | Slovenian Genialis raises ＄13M to improve diseases treatment with AI and ML
30 March, 2023, 10:24
Rostyslav Sobachynskyi --> --> --> -->--> --> --> --> --> --> --> --> -->
Genialis, a medtech compan... |
| 22.03.2023 | DEBIOPHARM ANNOUNCES LAUNCH OF THE PHASE 1/2 GaLuCi™ STUDY FOR ITS CA IX-TARGETED RADIOPHARMACEUTICAL PROGRAM | Debiopharm is developing personalized radiotherapy through a theranostic approach, combining diagnostic imaging (Debio 0328 a gallium-labelled imaging tool) and therapeutic components (Debio 0228, a lutetium-labelled radioligand), thus allo... |
| 09.03.2023 | Iktos raises €15.5 million Series A round for AI drug discovery service | French start-up Iktos has raised a €15.5 million Series A round fuelling its launch of its drug discovery platform.
Fresh to the Iktos cap table the round is co-led by M Ventures and Debiopharm Innovation Fund, and includes Omnes Capital.
I... |
| 02.03.2023 | DEBIOPHARM EXTENDS THEIR DNA DAMAGE REPAIR FOOTPRINT WITH NEW ONCOLOGY PIPELINE ENTRY | Debiopharm obtains global rights from Novo Nordisk for the development of their ubiquitin-specific protease 1 (USP1) inhibitor
LAUSANNE, Switzerland, March 2, 2023 /PRNewswire/ -- Debiopharm (www.debiopharm.com), an independent Swiss-based,... |
| 12.01.2023 | DEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS | - Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment.
- De... |
| 24.10.2022 | Interview: Thierry Mauvernay on his new book, the importance of listening to advice, and bridging the public and private sector | Interview: Thierry Mauvernay on his new book, the importance of listening to advice, and bridging the public and private sector 24.10.2022 12:00, Morgane Ghilardi linkedIn facebook twitter instagram youtube -->
Thierry Mauvernay, Preside... |
| 03.10.2022 | DEBIOPHARM REINFORCES THE BOND BETWEEN SWISS AND JAPANESE CANCER RESEARCH WITH THE 2022 JCA MAUVERNAY AWARD CEREMONY | Debiopharm awards the winning scientists for the JCA (Japanese Cancer Association) Award for innovative, disruptive, and translational oncology research
LAUSANNE, Switzerland, Oct. 3, 2022 /PRNewswire/ -- Debiopharm (www.debiopharm.com), a ... |
| 26.09.2022 | Debiopharm looks for an acquisition target in the ADC field | |
| 14.09.2022 | Debiopharm Co-leads a 10M USD Series A Round to Accelerate the Development of Genomic Medicines through Artificial Intelligence | Debiopharm Innovation Fund strategically invests in Whitelab Genomics' mission to make genomic medicine development faster and leaner for more efficient access to cancer patients in the future
LAUSANNE, Switzerland, Sept. 14, 2022 /PRNewswi... |
| 08.09.2022 | ONE DRUG FOR ONE BUG: DEBIOPHARM TO DISCUSS THE POTENTIAL OF PATHOGEN-SPECIFIC ANTIBIOTICS AT THE 2022 WORLD AMR CONGRESS | International health authorities, such as the WHO and the CDC are warning of the emerging danger of bacterial infections resistant to current antibiotics
The 2022 World Anti-Microbial Resistance (AMR) Congress in the greater Washington D.C.... |
| 07.09.2022 | Vanarix: The Venture Leader Biotech regenerating tissue to treat cartilage damage | Vanarix: The Venture Leader Biotech regenerating tissue to treat cartilage damage 07.09.2022 09:00, Tracy Woodley linkedIn facebook twitter instagram youtube -->
This fall, the Venture Leaders Biotech will represent Swiss innovation in t... |
| 09.05.2022 | Meet Mika: Berlin-based digital companion during cancer therapy raises €10 million | Digital solutions can fill many critical gaps in healthcare. Especially with regards to cancer therapy support, it can provide tremendous relief for patients and attending physicians alike. Betting big on digital therapeutics, Berlin-based ... |
| 14.04.2022 | DEBIOPHARM ANNOUNCES ONCOLOGY RESEARCH ADVANCEMENTS AT AACR 2022 FOR NOVEL CANCER COMPOUNDS AND DRUG DELIVERY TECHNOLOGIES | Pre-clinical & clinical exploratory poster presentations to highlight oncology results with
Debio 0123, xevinapant, and Multilink™ technology for antibody drug conjugates
LAUSANNE, Switzerland, April 14, 2022 /PRNewswire/ -- Debiopharm,... |
| 01.02.2022 | DEBIOPHARM AND ASPEN PARTNER TO LAUNCH PROSTATE CANCER DRUG TRELSTAR® IN SOUTH AFRICA | LAUSANNE, Switzerland and DURBAN, South Africa, Feb. 1, 2022 /PRNewswire/ -- Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company and Aspen, a South African headquartered multinational pharmaceutical company announced today th... |
| 16.12.2021 | Debiopharm Further Explores the Potential of its Potent, Highly Selective WEE1 Inhibitor Debio 0123 In Phase 1 Cancer Study | Dose escalation, monotherapy trial launched to access the safety and preliminary anti-tumor activity of Debio 0123 in the treatment of advanced solid tumors
LAUSANNE, Switzerland, Dec. 16, 2021 /PRNewswire/ -- Debiopharm (www.debiopharm.com... |
| 19.10.2021 | CARB-X Funds the 3rd Round of Debiopharm's Targeted Antibiotic Program to Combat Resistant N. gonorrhoeae Infections | LAUSANNE, Switzerland and BOSTON, Oct. 19, 2021 /PRNewswire/ -- Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company announced today having been awarded the third phase funding to advance the development of its an... |
| 07.10.2021 | Debiopharm and Dexa Medica Launch Triptorelin Collaboration to Bring New Hope to Women With Endometriosis | LAUSANNE, Switzerland and TANGERANG, Indonesia, Oct. 7, 2021 /PRNewswire/ -- Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, and Dexa Medica, a leading Indonesian pharmaceutical company, today announced the... |
| 04.10.2021 | Debiopharm Encourages Breakthrough Cancer Research in Japan Through its Competitive JCA Mauvernay Award | LAUSANNE, Switzerland, Oct. 4, 2021 /PRNewswire/ -- Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, today announced the two winners of the 17th annual JCA Mauvernay Award for breakthrough Japanese oncology r... |
| 03.12.2018 | Self-plus ravit le Challenge Debiopharm-Inartis 2018 | Normal 0 21 false false false FR-CH X-NONE X-NONE |
| 29.06.2017 | Challenge Debiopharm-Inartis récompense les six finalistes 2017 | |
| 09.05.2017 | BC Platforms Closes USD $10 million Series B Financing | |
| 07.03.2017 | Dirigé par une femme, Debiopharm Innovation Fund investit dans les smart datas | |
| 21.02.2017 | Appel à projets pour le Challenge Debiopharm Inartis | |
| 20.02.2017 | Debiopharm Innovation Fund looking for patient care startups | |
| 26.10.2016 | Coorpacademy lève 10 millions d’euros | |
| 31.08.2016 | GenePOC Receives Tens of Millions of Dollars from Debiopharm | GenePOC, a Canadian developer of rapid diagnostic devices which enable the prevention and detection of infectious diseases, received an investment of tens of millions of dollars.
Debiopharm Group, a Swiss-based global biopharmaceutical grou... |
| 11.07.2016 | Challenge Debiopharm Inartis : les quatre finalistes annoncés | |
| 10.02.2016 | Almost a billion invested in Venture Kick startups | |
| 16.06.2015 | Debiopharm acquires sample processing technology from Spinomix | |
| 18.12.2014 | Debiopharm Investment, Ardian, Nixdorf Foundation and Bernis acquire Eco Delta solar activities | |
| 17.11.2014 | Coorpacademy lève 3,8 millions de francs suisses | |
| 27.03.2014 | ICT Investor’s Day : la 3ème édition romande aura lieu le 12 mai à Lausanne | |
| 21.03.2014 | Most active Early Stage Investors in 2013 | |
| 07.03.2014 | Debiopharm plans to acquire companies and products | |
| 06.03.2014 | Immunexpress Raises $6M in Funding | Immunexpress Group, a Brisbane, Australia and Seattle, USA-based molecular diagnostic company, raised $6m in funding.
The round was led by Debiopharm Diagnostics SA, which is part of the Swiss-based global biopharmaceutical group of compani... |
| 09.01.2014 | Spinomix announces milestone payment and a new CEO | |
| 03.12.2013 | BPA Solutions closes financing round with Debiopharm Investment | |
| 18.09.2013 | Debiopharm Investment entre dans le capital de la Smallrivers | |
| 06.09.2013 | Debiopharm Group takes a stake in Skiioo, a start-up based in Vaud | |
| 03.09.2013 | KeyLemon Closes $1.5M Series A Funding | KeyLemon, a Martigny, Switzerland-based developer of face recognition software, closed a $1.5m Series A funding.
The round was led by Debiopharm Investment, a unit of the Debiopharm Group, and Swisscom Ventures.
The company intends to use t... |
| 02.09.2013 | KeyLemon secures Series A Investment | |
| 08.07.2013 | Quartz Bio supports Debiopharm Group | |
| 07.06.2013 | Diagnoplex closes a financing round led by Debiopharm Group | |
| 07.06.2013 | Diagnoplex Secures 1.3M Swiss Francs | Diagnoplex SA, a Lausanne, Switzerland-based developer of molecular diagnostics for colon cancer, has secured 1.3m Swiss francs.
The round was led by Debiopharm Diagnostics SA, part of the Swiss-based global biopharmaceutical group of compa... |
| 22.05.2013 | Urturn secures USD13.4m investment led by Balderton Capital | |
| 03.05.2013 | Eight start-ups selected for ICT Investor’s Day in Lausanne | |
| 17.01.2013 | Compliant concept: financing round and success in the market | |
| 10.01.2013 | Spinomix closes a USD3 Million financing round led by Debiopharm Group | |
| 09.01.2013 | Spinomix Closes $3M Series A Equity Funding | Spinomix SA, a Lausanne, Switzerland-based a life science company, closed a $3m Series A equity funding.
The round was led by drug development company Debiopharm Group, with participation from existing investors and a private US investor gr... |
| 20.12.2012 | Wer Erfolg hat, gibt der Start-up Community wieder etwas zurück | Frau Vonmont, künftig müssen die Firmengründer an venture kick eine Beteiligung an ihrem Unternehmen von bis zu 10 Prozent für das Startkapital von 130‘000 Franken abgeben. Haben Sie keine Angst, dass die Firmengründer durch dieses Beteilig... |
| 17.10.2012 | Searchbox closes investment round | |
| 26.09.2012 | venture kick supported start-ups created over 1600 new jobs | The privately funded initiative venture kick, which supports innovative start-up projects with up to CHF 130'000, celebrates its birthday. Five years ago, a jury pool of investors and experts met for the first time to carefully evaluate pro... |
| 05.07.2012 | Debiopharm Group invests in e-marketing platform Tweasy | |
| 22.06.2012 | Debiopharm, Immunexpress and Biocartis Announce Collaboration | |
| 20.06.2012 | Debiopharm Group supports venture kick | |
| 04.10.2011 | Prix Debiopharm 2011 : CHF 20000.- pour le projet le plus novateur | |
| 30.08.2011 | Affinium Pharmaceuticals Closes $15M Financing | Affinium Pharmaceuticals, an Austin, Texas,- and Toronto, Canada-based specialty pharmaceutical company focused on the development of novel anti-infective medicines, has closed a $15m financing.
Backers include Series A shareholders SV Life... |
| 18.01.2011 | Diagnoplex Receives Series A Financing from Debiopharm Group | Diagnoplex SA, a Lausanne, Switzerland-based developer of molecular diagnostics for colon cancer, has closed a series A financing extension with Debiopharm Group.
Under the terms of the agreement and subject to certain (undisclosed) milesto... |
| 16.10.2006 | CAT and Debiopharm Group enter into an exclusive agreement to develop and market SC-1 for... | CAT and Debiopharm Group enter into an exclusive agreement to develop and market SC-1 for...
16-10-2006
Cambridge, UK and Lausanne, Switzerland. Cambridge Antibody Technology (CAT) and The Debiopharm Group have entered into an exclusive wor... |
| - | Meet Mika: Berlin-based digital companion during cancer therapy raises €10 million | Digital solutions can fill many critical gaps in healthcare. Especially with regards to cancer therapy support, it can provide tremendous relief for patients and attending physicians alike. Betting big on digital therapeutics, Berlin-based ... |
